Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04293406 · ClinicalTrials.gov registry record
pCHIP: Prostate Cancer Health Impact Program
A clinical trial, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- 82
- Enrollment target
NCT04293406: Clinical Trial study, sponsored by Weill Medical College of Cornell University.
NCT04293406 is a clinical trial that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 82 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04293406 was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- 82 participants
- Enrollment target
Study Summary
This project focuses on African American (AA) men and Hispanic/Latino (H/L) men with prostate cancer (PCa) in Brooklyn/Queens catchment. Evidence from randomized clinical trials support the efficacy of decision navigation intervention, with navigated patients showing greater confidence in their decisions about cancer treatment and less regret. The investigators will develop and test the acceptability and feasibility of a decision navigation intervention for AA or H/L men with prostate cancer. The primary aim for this study is to adapt and tailor an evidence based decision navigation intervention for AA and H/L men newly diagnosed with prostate cancer (PCa). The investigators hypothesize that men in the decision navigation intervention arm will report higher levels of decision self-efficacy, less decisional conflict, and regret about their treatment decisions compared to men engaged in standard of care.
Primary Outcome
By conducting semi-structured interview, the investigators will adapt and tailor an evidence-based decision navigation intervention (DNI) for AA and H/L men diagnosed with prostate cancer. Semi-structured interviews consist of participant information and free-response questions. Participant information such as, contact information, health information, prostate cancer risk perception, basic demographic and chart abstractions will be recorded.
Interventions
- OTHER Decision Navigation Intervention (DNI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2021-02-10 |
| Est. Completion | 2024-04-01 |
Why NCT04293406 stopped before completion
NCT04293406 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 82 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Decision Navigation Intervention (DNI) is the first listed.
NCT04293406 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04293406 about?
NCT04293406 is a clinical study titled "pCHIP: Prostate Cancer Health Impact Program". This project focuses on African American (AA) men and Hispanic/Latino (H/L) men with prostate cancer (PCa) in Brooklyn/Queens catchment. Evidence from randomized clinical trials support the efficacy of decision navigation intervention, with navigated patients showing greater confidence in their deci...
What is the current status of trial NCT04293406?
This trial is currently terminated. The enrollment target is 82 participants. The study started on 2021-02-10. Estimated completion is 2024-04-01.
What interventions are being tested in trial NCT04293406?
The interventions under investigation include: Decision Navigation Intervention (DNI) (OTHER).
Who is sponsoring clinical trial NCT04293406?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03319901 · 82 participants · Phase 1
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
- NCT03493425 · 82 participants · Phase 2
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
- NCT04105270 · 82 participants · Phase 2
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
- NCT04428658 · 82 participants · NA
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI